The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · cited 3×
“…and erlotinib (Tarceva) have also shown efficacy in patients with NSCLC (Herbst et al., 2004), particularly in a subgroup of patients that have mutations in the EGFR kinase domain that are more susceptible to inhibition by these molecules (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004).”
BackgroundEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Carpenter, G., & Cohen, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38983-5 · Cited by 1,622
An Essential Role for Ectodomain Shedding in Mammalian Development
Peschon, J. J., Slack, J. L., Reddy, P., Stocking, K. L., Sunnarborg, S. W., Lee, D. C., Russell, W. E., Castner, B. J., Johnson, R. S., Fitzner, J. N., et al. (1998) · Science · doi:10.1126/science.282.5392.1281 · Cited by 1,607
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., & Ullrich, A. (1999) · Nature · doi:10.1038/47260 · Cited by 1,504
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α
Moss, M. L., Jin, S.-L. C., Milla, M. E., Burkhart, W., Carter, H. L., Chen, W.-J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., et al. (1997) · Nature · doi:10.1038/385733a0 · Cited by 1,378
Autocrine Secretion and Malignant Transformation of Cells
Sporn, M. B., & Todaro, G. J. (1980) · New England Journal of Medicine · doi:10.1056/nejm198010093031511 · Cited by 1,346
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227
ADAMs: key components in EGFR signalling and development
Blobel, C. P. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1548 · Cited by 1,090
Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands
Sahin, U., Weskamp, G., Kelly, K., Zhou, H.-M., Higashiyama, S., Peschon, J., Hartmann, D., Saftig, P., & Blobel, C. P. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200307137 · Cited by 979
Serum-free cell culture: a unifying approach
Barnes, D., & Sato, G. (1980) · Cell · doi:10.1016/0092-8674(80)90540-1 · Cited by 959
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 950
Harris, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00105-2 · Cited by 776
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698 · cited 1×
“Among them, EGFR, HER2, and HER4 have tyrosine kinase activities; HER3 has a truncated kinase domain, which is not functional, and thus can signal only in the context of receptor heterodimerization (Guy et al., 1994).”
BackgroundAberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer‐Müller, S., Fong, K. M., Virmani, A. K., Geradts, J., Gazdar, A. F., & Minna, J. D. (2001) · PubMed · Cited by 608
Self-citationCooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Fiore, P. P. D., & Kraus, M. H. (1995) · PubMed · Cited by 548
Engelman, J. A., Jänne, P. A., Mermel, C., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 493
Wong, S. T., Winchell, L. F., McCune, B. K., Earp, H. S., Teixido, J., Massague, J., Herman, B., & Lee, D. C. (1989) · Cell · doi:10.1016/0092-8674(89)90252-3 · Cited by 475
Amann, J., Kalyankrishna, S., Massion, P. P., Ohm, J. E., Girard, L., Shigematsu, H., Peyton, M., Juroske, D., Huang, Y., Stuart Salmon, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.226.65.1 · Cited by 436
Self-citationTransmembrane TGF-α precursors activate EGF/TGF-α receptors
Brachmann, R., Lindquist, P. B., Nagashima, M., Kohr, W., Lipari, T., Napier, M., & Derynck, R. (1989) · Cell · doi:10.1016/0092-8674(89)90591-6 · Cited by 422
Sunnarborg, S. W., Hinkle, C. L., Stevenson, M., Russell, W. E., Raska, C. S., Peschon, J. J., Castner, B. J., Gerhart, M. J., Paxton, R. J., Black, R. A., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112050200 · Cited by 413
Gefitinib — a novel targeted approach to treating cancer
Herbst, R. S., Fukuoka, M., & Baselga, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1506 · Cited by 401
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
Tracy, S., Mukohara, T., Hansen, M., Meyerson, M., Johnson, B. E., & Jänne, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1905 · Cited by 374
Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)
Huang, S., Armstrong, E. A., Benavente, S., Chinnaiyan, P., & Harari, P. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0562 · Cited by 366
Bachman, K. E., Herman, J. G., Corn, P. G., Merlo, A., Costello, J., Cavenee, W. K., Baylin, S. B., & Graff, J. R. (1999) · PubMed · Cited by 358
Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity
Roghani, M., Becherer, J. D., Moss, M. L., Atherton, R. E., Erdjument-Bromage, H., Arribas, J., Blackburn, R. K., Weskamp, G., Tempst, P., & Blobel, C. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.6.3531 · Cited by 319
Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S., Lindeman, N., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 318
Yan, Y., Shirakabe, K., & Werb, Z. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200112026 · Cited by 315
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
Mendelsohn, J. M. (1997) · PubMed · Cited by 311
Matar, P., Rojo, F., Cassia, R., Moreno-Bueno, G., Di Cosimo, S., Tabernero, J., Guzmán, M., Rodriguez, S., Arribas, J., Palacios, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0870 · Cited by 277
TACE is required for the activation of the EGFR by TGF-α in tumors
Borrell-Pagès, M., Rojo, F., Albanell, J., Baselga, J., & Arribas, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg111 · Cited by 274
Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Dong, J., Opresko, L. K., Dempsey, P. J., Lauffenburger, D. A., Coffey, R. J., & Wiley, H. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6235 · Cited by 263
The role of EGF-related peptides in tumor growth
Normanno, N. (2001) · Frontiers in Bioscience · doi:10.2741/a635 · Cited by 216
Kim, H. H., Sierke, S. L., & Koland, J. G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31455-2 · Cited by 196
Horiuchi, K., Zhou, H.-M., Kelly, K., Manova, K., & Blobel, C. P. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2005.05.004 · Cited by 163
Montero, J. C., Yuste, L., Dı́az-Rodrı́guez, E., Esparı́s-Ogando, A., & Pandiella, A. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0896 · Cited by 162
Bian, J., Wang, Y., Smith, M. R., Kim, H., Jacobs, C., Jackman, J., Kung, H., Colburn, N. H., & Sun, Y. (1996) · Carcinogenesis · doi:10.1093/carcin/17.9.1805 · Cited by 149
Oncogenic growth factor receptors: implications for signal transduction therapy
Mosesson, Y., & Yarden, Y. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.04.005 · Cited by 143
Merlos‐Suárez, A., Ruíz-Paz, S., Baselga, J. M., & Arribas, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103488200 · Cited by 132
Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene
Valenzuela, D., & Groffen, J. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.2.843 · Cited by 86
Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas.
Gorgoulis, V. G., Aninos, D., Mikou, P., Kanavaros, P., Karameris, A., Joardanoglou, J., Rasidakis, A., Veslemes, M., Ozanne, B. W., & Spandidos, D. A. (1992) · PubMed · Cited by 84
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
Cappuzzo, F., Toschi, L., Domenichini, I., Bartolini, S., Ceresoli, G. L., Rossi, E., Ludovini, V., Cancellieri, A., Magrini, E., Bemis, L., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602865 · Cited by 77
Liu, X., Fridman, J. S., Wang, Q., Caulder, E., Yang, G., Covington, M. B., Liu, C., Marando, C. A., Zhuo, J., Li, Y., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.6.2707 · Cited by 61
Self-citationvan der Horst, E. H., Murgia, M., Treder, M., & Ullrich, A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20867 · Cited by 56
Gollamudi, M., Nethery, D. E., Liu, J., & Kern, J. A. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2003.08.027 · Cited by 55
O‐charoenrat, P., Rhys‐Evans, P. H., & Eccles, S. A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10531 · Cited by 47
ADAM proteases, ErbB pathways and cancer
Zhou, B. S., Fridman, J. S., Liu, X., Friedman, S., Newton, R. C., & Scherle, P. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.591 · Cited by 23
Self-citation
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Jänne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,052
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
Metadata
- Authors
- Zhou, B.-B. S., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y., Baribaud, F., Mikami, I., Reguart, N., Yang, G., Li, Y., Yao, W., Vaddi, K., Gazdar, A. F., Friedman, S. M., Jablons, D. M., Newton, R. C., Fridman, J. S., Minna, J. D., & Scherle, P. A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2006-07
- Volume
- 10
- Issue
- 1
- Pages
- 39-50
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2090685720
- Cited by
- 374
- References
- 55
- FWCI
- 14.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.